The Precautionary and Prohibited Medications Database
Maintained by a collaboration of the University at Buffalo Pharmacology Specialty Laboratory and Frontier Science & Technology Research Foundation
COVID-19 Resources:
To go directly to the list of all COVID-19 medications, click here.
Maintained by a collaboration of the University at Buffalo Pharmacology Specialty Laboratory and Frontier Science & Technology Research Foundation
The precautionary and prohibited medications database is a utility for investigators to use during protocol development and implementation
The Precautionary and Prohibited Medications Database was created to assist AIDS Clinical Trials Group (ACTG) investigators and research staff during protocol development and the conduct of clinical studies. Investigators and research staff may access the most current pharmacokinetic data regarding drug-drug interactions for medications utilized in each of several ACTG scientific focus areas. More information on ACTG research focus areas can be found at the following web address: https://actgnetwork.org/committees/scientific
The data in the database comes from a variety of sources, such as research conferences and publications. Learn More
| First Medication | Second Medication | Designation | View |
|---|---|---|---|
| Darunavir/Cobicistat | Rifapentine/Isoniazid | Prohibited | View |
| Glecaprevir/Pibrentasvir | Atazanavir | Prohibited | View |
| Glecaprevir/Pibrentasvir | Efavirenz | Prohibited | View |
| Glecaprevir/Pibrentasvir | Darunavir/Ritonavir | Prohibited | View |
| Number of Drugs | 359 |
|---|---|
| Number of Interactions | 905 |